Altaris Takes Simulations Plus Private for $375M: What Healthcare PE Is Betting On

TL;DR: On June 16, 2026, Altaris Capital Partners announced a $375 million all-cash deal to take Simulations Plus (Nasdaq: SLP) private at $18.50 per share, a 26% premium to the 60-day volume-weighted average price. The deal closes in Q4 2026. Post-close, Altaris plans to combine Simulations Plus with Chemical Computing Group (CCG), a Montreal-based molecular design software firm already in its portfolio. The combined entity would cover the full computational drug discovery stack, from molecular design through ADMET prediction and pharmacokinetic simulation. This is a disciplined, data-first bet by a firm with $9 billion-plus in equity under management and a 23-year track record in healthcare.

The Deal: Exact Numbers and Structure

Let me give you the facts straight. Altaris Capital Partners agreed to acquire all outstanding shares of Simulations Plus for $18.50 per share in cash, valuing the company at approximately $375 million. The 26% premium is measured against the 60-day volume-weighted average price as of June 15, 2026. That is not a desperate seller taking a haircut. That is a public market that underpriced a niche software business with defensible recurring revenue and 30 years of proprietary data.

The financing structure is clean. Altaris is funding the deal through committed equity and debt from its own affiliated funds, with no financing contingency. The acquiring entity is SP Evolution HoldCo II, LLC, with SP Evolution BidCo II, LLC merging into Simulations Plus to create a wholly-owned subsidiary.

Simulations Plus co-founder Dr. Walter Woltosz signed a voting support agreement to vote all of his shares in favor of the transaction. The board approved the deal unanimously. Shareholders will vote at a special meeting, and the deal requires customary regulatory approvals from the SEC and antitrust review. Expect a Q4 2026 close barring surprises.

The target company recently relocated from California to Research Triangle Park, North Carolina, putting it closer to the pharma and biotech corridor its customers inhabit. That is not a cosmetic move.

What Simulations Plus Actually Does

If you have never heard of Simulations Plus, you are not alone. It does not make drugs. It makes the software that helps drug companies decide which molecules are worth developing in the first place. That distinction matters enormously to a PE investor because it means Simulations Plus sits upstream of the clinical and regulatory risk that has burned so many biotech investors.

The flagship product is ADMET Predictor, an AI and machine learning platform that predicts more than 175 ADMET properties, meaning absorption, distribution, metabolism, excretion, and toxicity endpoints. Give it a molecular structure. It tells you predicted aqueous solubility, pKa values, CYP and UGT metabolism pathways, Ames mutagenicity risk, drug-induced liver injury potential, and systemic pharmacokinetics. That output feeds directly into GastroPlus, the company's physiologically-based pharmacokinetic simulation engine, which models how a drug will behave in a human body before a single dose is given to a patient.

This is not experimental technology. Simulations Plus has a 30-year heritage in ADMET and pharmacokinetic modeling, with platforms adopted by major pharmaceutical companies, biotech firms, and drug regulators worldwide. When a drug company files a new drug application, PBPK modeling data generated by tools like GastroPlus often appear in the submission itself. That is regulatory stickiness you cannot manufacture overnight.

ADMET Predictor also includes an AI-driven drug design module that automates generative chemistry workflows, combining high-throughput pharmacokinetic and ADMET predictions with structure generation. A medicinal chemist can iterate on thousands of candidate molecules in the time it used to take to evaluate dozens.

Who Altaris Is

Altaris Capital Partners was founded in 2003 by George Aitken-Davies and Daniel Tully, both veterans of Merrill Lynch's healthcare investment banking and private equity operations. Aitken-Davies ran Merrill's private equity healthcare work. Tully was global head of healthcare equity capital markets. These are not generalists who wandered into healthcare. They built their careers inside the sector and have spent more than two decades deploying capital exclusively within it.

Today the firm manages more than $9 billion in equity capital and has invested in more than 50 healthcare companies since inception. The portfolio spans payers, providers, healthcare technology, and now drug development software. Their recent deal history is instructive for understanding how Altaris thinks about platform building.

In January 2026, Altaris acquired Tegria Services Group, a healthcare technology services firm spun out of Providence St. Joseph Health. Tegria provides outsourced technology and operational services to health systems, giving Altaris 22-plus payer and provider services relationships and deep integration into hospital IT infrastructure.

Before that, in October 2024, Altaris completed its acquisition of Sharecare at $1.43 per share, taking the digital health platform private as a standalone business. That deal showed the firm's comfort with consumer-facing digital health platforms built on recurring engagement models.

Simulations Plus fits a different part of the portfolio. It is enterprise software for pharmaceutical R&D departments, with long contract cycles and high switching costs. That is exactly the type of revenue stream a PE firm wants during a period of macro uncertainty.

The Combination Thesis: Simulations Plus and CCG

Here is where the deal gets strategically interesting. Altaris does not plan to run Simulations Plus as a standalone asset. The firm has stated its intention to combine Simulations Plus with Chemical Computing Group, a Montreal-based company founded in 1994 that is already in the Altaris portfolio.

CCG makes the Molecular Operating Environment, known as MOE. MOE is the industry-standard software for computer-aided molecular design at the pre-clinical stage. Drug discovery teams use MOE to visualize protein structures, model ligand binding, and design molecules from scratch using structural biology data. MOE has been adopted by pharmaceutical and biotech firms for more than 30 years. It has the same kind of embedded customer loyalty that ADMET Predictor enjoys, built on deep scientific credibility rather than marketing spend.

Put the two platforms together and you get a computational drug discovery stack that covers the full hit-to-lead and lead-optimization workflow. A scientist uses MOE to design candidate molecules using structural biology. ADMET Predictor then screens those candidates for absorption, metabolism, and toxicity risk. GastroPlus simulates how the best candidates will behave in the body at the system level. Each step informs the next. The data generated at each stage feeds back into the AI models that improve future predictions.

That is the value creation thesis. Altaris is not buying a software tool. It is assembling a proprietary data network that becomes more predictive the more it is used. Every drug company running discovery programs through this combined platform adds to the training data that improves the models.

I want to be direct about what Altaris has not disclosed. Will MOE and ADMET Predictor be architected as a unified platform or sold as complementary tools? That question matters for pricing power and customer experience. The answer will determine how quickly Altaris can realize cross-sell revenue from two well-regarded but independently operated businesses.

What This Signals About Healthcare Software PE in 2026

Healthcare IT M&A in 2026 is bifurcating sharply. Buyers are paying premium multiples for a small category of assets: platforms with proprietary training data, defensible predictive models, measurable ROI for customers, and high switching costs. Everything else is being repriced downward or left on the shelf entirely.

Simulations Plus fits the premium category on every dimension. The 175-plus ADMET property predictions in ADMET Predictor are built on decades of experimental data that no startup can replicate quickly. The GastroPlus PBPK simulation engine is embedded in regulatory submissions at the FDA and EMA. The customer relationships are long-term and contract-based. A drug company that builds its discovery workflows around these tools does not switch vendors mid-program. The cost of switching is measured in years of re-validation work, not software license fees.

PwC's 2026 health industries M&A outlook identified AI-enabled productivity platforms with recurring cash flows as the primary target for financial buyers. The 26% premium validates that buyers pay above market for software with genuine AI capability built on proprietary scientific data rather than general-purpose models fine-tuned on public datasets.

Healthcare PE is moving away from assets with direct reimbursement exposure toward software platforms where revenue depends on pharmaceutical R&D budgets rather than CMS fee schedules. Drug development software sits outside the reimbursement system entirely, insulating it from Medicare drug price negotiation and biosimilar pressure that are compressing margins elsewhere.

With roughly $2.5 trillion in PE dry powder entering 2026, competition for premium healthcare software assets is intense. Altaris moved before a strategic acquirer like Certara or Schrodinger could make a competing bid. The all-cash structure with no financing contingency was designed to create certainty for shareholders quickly.

The Accredited Investor Angle

You cannot buy into this specific deal. Simulations Plus shareholders receive $18.50 per share and exit. Altaris funds are not accessible to retail investors. But if you want exposure to the healthcare software PE strategy that produced this deal, you have a few paths worth understanding.

First, blind pool PE funds targeting healthcare technology offer the closest analog. These vehicles deploy across multiple platform acquisitions over a three-to-five-year period. You back the manager's thesis and track record rather than selecting individual deals. Firms with dedicated healthcare IT mandates are actively deploying into the same category Altaris is targeting: enterprise software with proprietary data and high switching costs.

Second, business development companies, known as BDCs, sometimes provide debt financing to PE-backed healthcare software companies. BDCs are publicly traded, pay regular dividends funded by interest income, and give investors a way to earn yield from the private credit that funds PE buyouts. You are a creditor, not an owner, but the income stream is more predictable and senior in the capital structure.

Third, secondary market transactions allow accredited investors to buy LP interests in existing PE funds from investors who need liquidity. If you want exposure to Altaris's current portfolio today, the secondary market is the most direct path. Pricing depends on the fund's vintage year, deployment status, and current net asset value. Discounts to NAV have narrowed significantly in 2025 and 2026 as secondary fund supply has grown and well-capitalized buyers have competed aggressively for quality positions.

What Could Go Wrong

This deal could blow up in several ways, and I think you deserve a straight accounting of the risks.

Integration complexity is the largest operational risk. Combining Simulations Plus and CCG means merging two distinct scientific software platforms, two customer bases, and two engineering teams across North Carolina and Montreal. Drug discovery workflows are highly specialized. A disruption to a medicinal chemist mid-program could cost a customer relationship that took years to validate internally.

Competition from better-funded rivals is a real threat. Schrodinger has a market capitalization multiple times the $375 million Altaris is paying here, and it is investing heavily in AI-driven drug design. Certara covers the biosimulation space with a broader product line and larger sales team. New entrants backed by generative AI funding are building cloud-native tools that target the same workflows. Proprietary data advantages erode when competitors train on growing public molecular databases.

Debt load post-close is an unknown. The equity-to-debt split has not been disclosed. If the combined entity carries significant leverage, it faces pressure to generate cash flow quickly. That pressure conflicts with the long-horizon R&D investments required to build a genuinely integrated platform. Cutting product investment to service debt has destroyed value in software buyouts before.

Regulatory and data governance risk is emerging. The FDA and EMA are developing clearer frameworks for validating AI-generated ADMET predictions in regulatory submissions. New validation requirements could impose significant compliance costs. Customers may also push back on data governance terms if Altaris attempts to aggregate and monetize proprietary experimental data generated by pharmaceutical clients.

The Bottom Line

The $375 million Altaris-Simulations Plus deal is a clean expression of where healthcare PE is placing its bets in 2026: proprietary data, embedded workflows, AI capability with scientific credibility, and revenue streams decoupled from reimbursement risk. The combination with CCG could create a differentiated asset in computational drug discovery. The integration work ahead is harder than any press release will acknowledge. But the strategic logic is sound, and the deal price reflects a market learning to value scientific software on its own terms.

Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.